Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin

Kidney International

Volumn 68, Issue 3, 2005, Pages 1337-1343

  Fishbane, Steven ^a   Berns, Jeffrey S ^a  

^a NONE

Author keywords

Anemia; Erythropoietin; Iron; Pharmacology

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG DOSE REDUCTION; FEMALE; HEMODIALYSIS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PHENOMENOLOGY; PRIORITY JOURNAL; TIME SERIES ANALYSIS;

EID: 32644457068     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00532.x     Document Type: Article

References (28)

1. KOCH KM, PATYNA WD, SHALDON S, WERNER E: Anemia of the regular hemodialysis patient and its treatment. Nephron 12:405-419, 1974
2. SCHAEFER RM, KUERNER B, et al: Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Int J Artif Organs 11:249-254, 1988
3. ESCHBACH JW, EGRIE JC, DOWNING MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
4. ESCHBACH JW, ABDULHADI MH, BROWNE JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
5. COLLINS AJ, MA JZ, EBBEN J: Impact of hematocrit on morbidity and mortality. Semin Nephrol 20:345-349, 2000
6. COLLINS AJ, LI S, ST PETER W, et al: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465-2473, 2001
7. BERNS JS, ELZEIN H, LYNN RI, et al: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64:1514-1521, 2003
8. LACSON E JR., OFSTHUN N, LAZARUS JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41:111-124, 2003
9. PATTERSON P, ALLON M: Prospective evaluation of an anemia treatment algorithm in hemodialysis patients. Am J Kidney Dis 32:635-641, 1998
10. NATIONAL KIDNEY FOUNDATION: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37(Suppl 1):S182-S238, 2001
11. TONELLI M, BLAKE PG, MUIRHEAD N: Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 47:82-85, 2001
12. CHEUNG W, MINTON N, GUNAWARDENA K: Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 57:411-418, 2001
13. YAQUB MS, LEISER J, MOLITORIS BA: Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol 21:390-396, 2001
14. ROBERTS TL, OBRADOR GT, ST PETER WL, et al: Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 66:2429-2436, 2004
15. GUNNELL J, YEUN JY, DEPNER TA, KAYSEN GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33:63-72, 1999
16. FISHBANE S, MITTAL SK, MAESAKA JK: Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int (Suppl 69):S67-S70, 1999
17. FISHBANE S, LYNN RI: The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44:238-240, 1995
18. LONGNECKER RE, GOFFINET JA, HENDLER ED: Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 20A:135-140, 1974
19. SEMENZA GL, WANG GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447-5454, 1992
20. FANDREY J: Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 288:R977-R988, 2004
21. ADAMSON JW: Erythropoietin: Its role in the regulation of erythropoiesis and as a therapeutic in humans. Biotechnology 19:351-363, 1991
22. O'RIORDAN E, FOLEY RN: Effects of anaemia on cardiovascular status. Nephrol Dial Transplant 15 (Suppl 3):19-22, 2000
23. SADOSHIMA J, IZUMO S: Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 73:424-438, 1993
24. FARRELL F, LEE A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 (Suppl 5):18-30, 2004
25. CERAMI A, BRINES ML, GHEZZI P, CERAMI CJ: Effects of epoetin alfa on the central nervous system. Semin Oncol 28(2 Suppl 8):66-70, 2001
26. KILIC U, KILIC E, SOLIZ J, et al: Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J 19:249-251, 2005
27. BOGOYEVITCH MA: An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63:208-216, 2004
28. WESTENFELDER C: Unexpected renal actions of erythropoietin. Exp Nephrol 10:294-298, 2002